GLP-1s & Next-Gen Agonists

Semaglutide vs tirzepatide vs retatrutide (and related agents).

Semaglutide
Ozempic, Wegovy
FDA Approved

GLP-1 receptor agonist

Starting Dose
0.25mg weekly
Half-life
~7 days
US Price
$75
Research Articles
1,345
Top Outcomes (Clinical / Community)
Weight Loss: A / B
Blood Sugar Control: A / B
Sleep Quality: C / B
Appetite Suppression: A / B
Tirzepatide
Mounjaro, Zepbound
FDA Approved

GLP-1/GIP dual receptor agonist

Starting Dose
2.5mg weekly
Half-life
~5 days
US Price
$100
Research Articles
477
Top Outcomes (Clinical / Community)
Weight Loss: A / B
Sleep Quality: A / B
Appetite Suppression: A / B
Blood Sugar Control: A / B
Retatrutide
LY3437943
Phase 3 Trials

GLP-1/GIP/Glucagon triple receptor agonist

Starting Dose
1-2mg weekly (research protocols)
Half-life
~6 days (estimated)
US Price
$100
Research Articles
32
Top Outcomes (Clinical / Community)
Weight Loss: A / B
Appetite Suppression: A / B
Sleep Quality: C / B
Energy Levels: D / B
Phase 3 Trials

Long-acting amylin receptor agonist

Starting Dose
0.3mg weekly (research protocols)
Half-life
~7 days
US Price
$80
Research Articles
11
Top Outcomes (Clinical / Community)
Appetite Suppression: B / B
Weight Loss: A / B
Sleep Quality: D / B
Energy Levels: C / B